Preferred Label : drug design;
MeSH definition : The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme
inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties
such as activity of functional groups, molecular geometry, and electronic structure,
and also on information cataloged on analogous molecules. Drug design is generally
computer-assisted molecular modeling and does not include pharmacokinetics, dosage
analysis, or drug administration analysis.;
MeSH synonym : drug designs; Pharmaceutical Design; Design, Pharmaceutical; Pharmaceutical Designs;
CISMeF synonym : Designs, Pharmaceutical; design, drug; designs, drug;
MeSH hyponym : drug modeling; Drug Modelings; Modeling, Drug; Modelings, Drug; Computer Aided Drug Design; Computer-Aided Drug Designs; Design, Computer-Aided Drug; Designs, Computer-Aided Drug; Drug Design, Computer-Aided; Drug Designs, Computer-Aided; Computerized Drug Design; Computerized Drug Designs; Design, Computerized Drug; Designs, Computerized Drug; Drug Design, Computerized; Drug Designs, Computerized;
MeSH annotation : no qualif; do not confuse with DESIGNER DRUGS; do not confuse with DESIGNER DRUGS;
Wikipedia link : https://en.wikipedia.org/wiki/Drug design;
Origin ID : D015195;
UMLS CUI : C0013171;
Allowable qualifiers
Automatic exact mappings (from CISMeF team)
Record concept(s)
See also
Semantic type(s)
The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme
inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties
such as activity of functional groups, molecular geometry, and electronic structure,
and also on information cataloged on analogous molecules. Drug design is generally
computer-assisted molecular modeling and does not include pharmacokinetics, dosage
analysis, or drug administration analysis.
https://www.has-sante.fr/jcms/p_3576102/fr/sam-de-l-ansm-sur-le-valproate-modification-des-conditions-de-prescription-et-de-delivrance-cpd-pour-les-patients-adolescents-et-hommes-afin-de-limiter-les-risques-potentiels-de-troubles-neurodeveloppementaux-pour-les-enfants-a-naitre-lies-a-l-exposition-paternelle-dans-les-trois-mois-precedant-la-conception
2025
France
evaluation of the transparency committee
indexing
medical futility
child
conception
meconium aspiration syndrome
adolescence
patients
macrophage activation syndrome
risk
paternal exposure
prescription, nos
men
adolescent
Neurodevelopmental Disorders
decision support techniques
father, nos
drug design
operations research
drug, nos
valproic acid
valproate
has patient
delivery, obstetric
effects of exposure to external cause, nos
mosaic variegated aneuploidy syndrome
Abstracting and Indexing
child, nos
valproate
---
https://dumas.ccsd.cnrs.fr/dumas-04623797
2024
France
dissertations, academic
Therapeutic Procedure
Treatment
Under No Medication
Pharmacologic Substance
Patient
has patient
Conception
methods
Conception Age
Object Class
drug therapy
therapeutics
PRETEXT Stage 2
drug, nos
patients
PRETEXT Stage 3
PRETEXT Stage 4
filing
No Information Available
Filed
drug design
CDISC SEND Study Design Terminology
Proposal
Therapeutic
Design
PRETEXT Stage 1
proposita
conception
---
https://www.theses.fr/2022UPASR008
2022
France
dissertations, academic
Analysis methods
Analysis methods
statistics
Exhibition
effects of exposure to external cause, nos
Statistics
protestantism
Analysis methods
drug modeling
statistics as topic
drug action, nos
drug design
Analysis methods
---